Literature DB >> 8466762

Treatment of relapsing anal carcinoma.

G Tanum1.   

Abstract

Between 1983 and 1989, a total of 94 patients were admitted to the Norwegian Radium Hospital for primary squamous cell carcinoma (including 'basaloid' and 'cloacogenic' carcinomas) of the anal canal. Seven patients with evident distant metastases received chemotherapy, while without known distant metastases received combined chemo- and radiotherapy. Of the latter patients, 17 developed distant metastases and 11 local recurrence later on. Patients with distant metastases had a median survival of 12 months (range 3-54 months) following start of chemotherapy (cisplatin + 5-FU or mitomycin C + 5-FU). An abdominoperineal resection was performed on 9 of the 11 patients with local relapse. Of these, 6 patients were alive without evident disease after 3 years of observation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8466762     DOI: 10.3109/02841869309083882

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

Review 1.  Pharmacotherapy of Anal Cancer.

Authors:  Jane E Rogers; Cathy Eng
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Anal cancer treatment: current status and future perspectives.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Pamela Abdayem; Joelle Antoun; Dolly Nasr
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 3.  Systemic Therapies for Advanced Squamous Cell Anal Cancer.

Authors:  Francesco Sclafani; Sheela Rao
Journal:  Curr Oncol Rep       Date:  2018-05-04       Impact factor: 5.075

4.  Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy.

Authors:  B C van der Wal; B I Cleffken; B Gulec; H S Kaufman; M A Choti
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

5.  Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.

Authors:  Francesco Sclafani; Federica Morano; David Cunningham; Chiara Baratelli; Eleftheria Kalaitzaki; David Watkins; Naureen Starling; Ian Chau; Sheela Rao
Journal:  Oncologist       Date:  2017-02-16

6.  Stage IV anal canal squamous cell carcinoma with long-term survival: a case report.

Authors:  Katsuji Sawai; Takanori Goi; Noriyuki Tagai; Hidetaka Kurebayashi; Mitsuhiro Morikawa; Kenji Koneri; Masato Tamaki; Makoto Murakami; Yasuo Hirono; Hiroyuki Maeda
Journal:  Surg Case Rep       Date:  2022-06-20

7.  Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.

Authors:  W E Longo; A M Vernava; T P Wade; M A Coplin; K S Virgo; F E Johnson
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

8.  A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature.

Authors:  Rosana Gnanajothy; Graham W Warren; Sherry Okun; Lindsay L Peterson
Journal:  J Gastrointest Oncol       Date:  2016-06

9.  Clinical Practice Guideline: Anal Cancer—Diagnosis, Treatment and Follow-up

Authors:  Robert Siegel; Ricardo Niklas Werner; Stephan Koswig; Matthew Gaskins; Claus Rödel; Felix Aigner
Journal:  Dtsch Arztebl Int       Date:  2021-04-02       Impact factor: 8.251

10.  International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.

Authors:  Sheela Rao; Francesco Sclafani; Cathy Eng; Richard A Adams; Marianne G Guren; David Sebag-Montefiore; Al Benson; Annette Bryant; Clare Peckitt; Eva Segelov; Amitesh Roy; Matt T Seymour; Jack Welch; Mark P Saunders; Rebecca Muirhead; Peter O'Dwyer; John Bridgewater; Shree Bhide; Rob Glynne-Jones; Dirk Arnold; David Cunningham
Journal:  J Clin Oncol       Date:  2020-06-12       Impact factor: 44.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.